The changing landscape in management of desmoplastic melanoma

Jonathan A Dunne¹, George Adigbli^{1

2}

Affiliations

¹ Department of Plastic Surgery, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
² Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Editorial

Jonathan A Dunne et al. J Surg Oncol. 2022 Feb.

. 2022 Feb;125(2):227-228.

doi: 10.1002/jso.26677. Epub 2021 Sep 17.

Jonathan A Dunne¹, George Adigbli^{1

2}

¹ Department of Plastic Surgery, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
² Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

No abstract available

References

1. Lawrence NF, Hammond MR, Frederick DT, et al. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): a clinicopathologic analysis of predictors of outcome. J Am Acad Dermatol. 2016;75:595-602.
1. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28(1):518-525.
1. Varey A, Goumas C, Hong AM, et al. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Mod Pathol. 2017;30(11):1538-1550.
1. Dunne JA, Wormald JC, Steele J, Woods E, Odili J, Powell BW. Is sentinel lymph node biopsy warranted for desmoplastic melanoma? A systematic review. J Plast Reconstr Aesthet Surg. 2017;70(2):274-280.
1. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347-350.